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Abstract
Background: Locoregional hyperthermia combined with radiotherapy significantly improves locoregional control
and overall survival for cervical tumors compared to radiotherapy alone. In this study biological modelling is
applied to quantify the effect of radiosensitization for three cervical cancer patients to evaluate the improvement in
equivalent dose for the combination treatment with radiotherapy and hyperthermia.
Methods: The Linear-Quadratic (LQ) model extended with temperature-dependent LQ-parameters α and β was
used to model radiosensitization by hyperthermia and to calculate the conventional radiation dose that is
equivalent in biological effect to the combined radiotherapy and hyperthermia treatment. External beam
radiotherapy planning was performed based on a prescription dose of 46Gy in 23 fractions of 2Gy. Hyperthermia
treatment using the AMC-4 system was simulated based on the actual optimized system settings used during
treatment.
Results: The simulated hyperthermia treatments for the 3 patients yielded a T50 of 40.1 °C, 40.5 °C, 41.1 °C and a T90
of 39.2 °C, 39.7 °C, 40.4 °C, respectively. The combined radiotherapy and hyperthermia treatment resulted in a D95 of
52.5Gy, 55.5Gy, 56.9Gy in the GTV, a dose escalation of 7.3–11.9Gy compared to radiotherapy alone (D95 = 45.0–45.5Gy).
Conclusions: This study applied biological modelling to evaluate radiosensitization by hyperthermia as a radiation-
dose escalation for cervical cancer patients. This model is very useful to compare the effectiveness of different
treatment schedules for combined radiotherapy and hyperthermia treatments and to guide the design of clinical
studies on dose escalation using hyperthermia in a multi-modality setting.
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Background
Achieving locoregional control is a challenge for locally
advanced cervix tumors (FIGO stage IIB-IV). Currently
combination of radiotherapy with concurrent cisplatin-
based chemotherapy is widely accepted as a standard
treatment [1–5]. An alternative is combining radiother-
apy with hyperthermia. Hyperthermia (i.e. increasing
tumor temperatures to 40–45 °C) is a very powerful
radio and chemosensitizer [6–9] improving clinical
outcome [10–12]. Several randomized clinical trials have
demonstrated that locoregional hyperthermia combined
with radiotherapy (thermoradiotherapy) is at least as ef-
fective in improving locoregional control for cervical tu-
mors as chemoradiotherapy [13–17]. The Dutch Deep
Hyperthermia Trial not only showed an 83 % local con-
trol rate for radiotherapy + hyperthermia versus 57 % for
radiotherapy alone, but also a 3-year overall survival of
51 % for radiotherapy combined with hyperthermia,
compared to 27 % with radiotherapy alone [13]. After
12 years survival is still almost twice as high after treat-
ment with thermoradiotherapy (37 %), versus 20 % with
radiotherapy [18]. A major advantage of hyperthermia
given sequentially before or after radiotherapy is that the
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incidence of late toxicity grade 3 or higher is not signifi-
cantly different from the toxicity reported after treat-
ment with radiotherapy alone. Thermoradiotherapy is
therefore often used as an alternative for the large num-
ber of stage IIB-IV patients unable to receive the stand-
ard therapy of concurrent chemotherapy and
radiotherapy, e.g. because of kidney failure. Local tumor
control achieved for standard therapy is good, particu-
larly if combined with image guided brachytherapy [19–
22], the challenge is still to improve control of regional
and distant disease and the reduction of side effects.
Hyperthermia may be effective in achieving these
objectives.
Planning for locoregional hyperthermia has become a
standard clinical procedure [23–25] but does not take
the synergy with radiotherapy into account. The radio-
sensitizing effect of hyperthermia can be considered as a
local increase in tumor dose, which can also be quanti-
fied using biological modelling [26, 27]. Hyperthermic
radiosensitization can be modelled as a change in the α
and ß parameters of the Linear Quadratic model [28–
30]. Recently a method has been presented to estimate
the effect of a hyperthermia treatment in terms of
equivalent dose distributions, i.e. the radiation dose that
has a biological effect equivalent to that of the combined
hyperthermia plus radiotherapy treatment. A conserva-
tive estimate of the temperature-dependency of the
modelling parameters was applied due to lack of pub-
lished temperature-dependent radiosensitivity data [31].
In this study biological modelling was applied for three
cervical cancer patients treated with radiotherapy (exter-
nal beam + brachytherapy) and hyperthermia to evaluate
the improvement in equivalent dose for this combined
treatment. The radiotherapy dose distribution was
matched onto the geometry of the hyperthermia data
set. Temperature-dependent parameters describing the
radiosensitivity were estimated from in vitro experiments
with a human cervical cancer cell line [29]. Hyperther-
mia treatments were simulated to evaluate the difference
in equivalent dose. Predicted temperature distributions
were compared to the measured tumor temperatures.
Methods
The workflow used consists of first computation of the
hyperthermia and radiotherapy dose distributions
followed by matching the radiotherapy dose distribution
onto the geometry of the hyperthermia CT scan and fi-
nally computation of the equivalent dose distribution
(Fig. 1).
Hyperthermia treatment planning
Hyperthermia treatment planning [25] is a standard clin-
ical procedure at the AMC and is based on a CT-scan in
hyperthermia treatment position, i.e. in supine position
on a water bolus and mattresses. Treatment planning
was performed using a non-commercial software pack-
age developed at the AMC. Hounsfield Unit based seg-
mentation was applied to segment the CT scan into
muscle, fat, bone and air [32], to which literature-based
dielectric and thermal tissue properties were assigned
(Table 1). The tumor was delineated manually by a radi-
ation oncologist. Hyperthermia treatment was simulated
for the AMC-4 locoregional heating device. Electric field
distributions in the patient were calculated at a reso-
lution of 2.5x2.5x2.5 mm3 by solving Maxwell’s equa-
tions with the Finite Difference Time Domain method
[33]. Antenna settings yielding an optimal steady-state
tumor temperature distribution were determined using
temperature-based optimization [34]. Heat-transfer com-
putations for perfused tissues were based on the Pennes
bio heat model [35]. In clinical hyperthermia tumor tem-
peratures are usually reported as T10, T50 and T90, i.e.
the temperature at least achieved in 10, 50 and 90 % of
the target volume, respectively [36, 37]. A tumor
temperature of 43 °C was the objective for optimization,
normal tissue temperatures were constrained to 45 °C.
Subsequently five weekly treatment sessions were
given during the period external beam irradiation was
given, one hour after a radiotherapy session. Hyperther-
mia was performed with the AMC-4 system consisting
of four 70 MHz waveguides around the pelvis of the pa-
tient, with water bags cooled to 13 °C between wave-
guide and skin provide coupling of energy and skin
cooling [38]. Thermometry consisted of thermocouple
Fig. 1 Workflow. The workflow used consists of first computation of
the hyperthermia and radiotherapy dose distributions, followed by
matching the radiotherapy dose distribution onto the geometry of
the hyperthermia CT scan and finally computation of the equivalent
dose distribution
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thermometry probes in the bladder, rectum and in a va-
ginal pelotte for temperature measurements during
hyperthermia, yielding measurement points bordering
the GTV. Phase settings during treatment are the pre-
planned settings, modified after performing phase
sweeps at the start of treatment [36], followed by a final
phase optimization using three delta T pulses to achieve
preferential heating of the cervix compared to bladder
and rectum [39]. The simulated tumor temperatures for
these phase and amplitude settings were used for bio-
logical modelling and were also compared with tempera-
tures measured during the first hyperthermia session.
The first session was chosen since the patient anatomy
during this session best matches the anatomy as deter-
mined during CT and are thus expected to yield more
reliable planning results than for later sessions.
Radiotherapy treatment planning
Radiotherapy treatment for locally advanced cervical
cancer consists of a combination of external beam and
MRI-guided brachytherapy. The prescription dose for
external beam irradiation was 46Gy in 23 fractions of
2Gy. External beam radiotherapy planning was per-
formed using Oncentra and based on a CT scan in prone
position on a belly board. External beam radiotherapy
was followed by a 24Gy brachytherapy boost using PDR
brachytherapy. Brachytherapy planning is based on an
MRI scan with the applicator in situ. The hyperthermia
treatment is unlikely to enhance the brachytherapy dose
since hyperthermia is only given during external beam
radiotherapy (EBRT) at the AMC and since there is a
gap of one week between the EBRT and brachytherapy
treatments. Thus we performed our evaluation for the
combination of hyperthermia and EBRT without involv-
ing the brachytherapy boost.
Image registration/matching
After treatment planning for both modalities, the next
step is matching the radiotherapy dose distribution onto
the geometry of the hyperthermia data set. To account
for organ displacement and deformation due to different
patient positioning (prone/supine) in the radiotherapy
and hyperthermia CT scans, deformable matching
software of Velocity Medical Solutions (Varian Medical
systems, Palo Alto) was used (Fig. 2). First, the radio-
therapy and hyperthermia CT scans were rigidly
matched by visual assessment of the bony anatomy.
Next, a deformable registration was made between the
EBRT CT and the hyperthermia CT using an intensity-
based deformable image registration algorithm. As this
study focusses on the effect of hyperthermia on the
tumor, accuracy of the deformable match was assessed
by warping contours of organs located close to the GTV
from the EBRT CT to the hyperthermia CT and verifying
that their location was sufficiently accurate. If not, these
organs were delineated on the hyperthermia scan as well
and a new deformable image registration was performed
(starting again from the rigid match), this time using a
hybrid algorithm combining both intensity and structure
based matching. The resulting deformation vector field
was used to warp the radiotherapy dose distribution to
the frame of reference of the hyperthermia CT.
Biological modelling
To quantify the therapeutic effect of radiosensitization
by hyperthermia, the radiotherapy dose distributions
combined with hyperthermia were converted to equiva-
lent radiation dose distributions (without hyperthermia
in 2Gy/fraction (EQD2)). Calculation of equivalent radi-
ation dose was based on the LQ-model [27], extended
with temperature-dependent LQ-parameters α(T) and
β(T) derived for cervical cancer cells in the hyperthermic
temperature range as is described in the next paragraph.
LQ-parameters
Franken et al [29] reported α and β values for a human
cervical cancer cell line (SiHa) at 37, 41 and 43 °C listed
in Table 2. These values were used to define the
temperature-dependent LQ-parameters α(T) and β(T)
for the entire hyperthermic range needed for the LQ-
model. The most significant change observed between
37 and 41 °C is an increase in β, whereas α increases
strongly between 41 and 43 °C. We therefore applied a
piecewise-linear interpolation for α(T) and β(T), consist-
ing of one linear segment valid between 37 and 41 °C
and another linear segment valid between 41 and 43 °C.
Table 1 Dielectric and thermal tissue properties used in hyperthermia treatment planning
Tissue type Conductivity σ Relative permittivity εr Density ρ Perfusion Wb Conductivity k Capacity c
[S m-1] [kg m-3] [kg m-3 s-1] [W m-1 K-1] [J kg-1 K-1]
Air 0 1 1.29 0 0.024 10,000a
Bone 0.05 10 1595 0.12 0.65 1420
Muscle 0.75 75 1050 3.6 0.56 3639
Fat 0.06 10 888 1.1 0.217 2387
Cervical tumor 0.74 65 1050 1.8 0.56 3639
aThe value of c used for air was tenfold increased to accelerate thermal computations. This has a negligible effect on the steady-state temperature (<2 × 10−5 °C)
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To evaluate the impact of using realistic temperature-
dependent LQ-parameters the outcome predicted by the
radiobiological model using this piecewise-linear
interpolation was then compared to the outcome using a
linear interpolation using only the data for α and β at 37
and 43 °C.
Equivalent dose calculations
Equivalent dose distributions for combined
radiotherapy-hyperthermia treatments were calculated
using the LQ-model [27]. The expression used for EQD2
calculation is:
EQD2 ¼ α Tð Þ⋅Dþ β Tð Þ⋅d⋅D
α 37ð Þ þ β 37ð Þ⋅2
with fraction dose d and total dose D and using the
temperature-dependent LQ-parameters α and β as de-
scribed in the previous section on LQ-parameters. Most
of the procedure is similar to the procedure used in the
simulation study of Kok et al. for prostate cancer [31].
Hyperthermic radiosensitization is assumed to be tumor
selective since radiotherapy and hyperthermia are given
sequentially with a time interval of at least 1 h [40–42].
The temperature-dependent LQ-parameters α and β
were thus only applied within the Gross Tumor Volume
(GTV), elsewhere α and β were assumed to remain
unchanged.
Results
Temperature and Dose Volume Histogram
The temperature volume histograms indicating the
tumor temperature distribution are shown in Fig. 3. The
corresponding T10, T50 and T90 values are listed in
Table 3 as well as the temperature measured during the
first treatment session. The effect of adding hyperther-
mia is shown in the cumulative Dose Volume Histo-
grams (DVH) in Fig. 4. These are computed assuming
either a linear or a piecewise-linear temperature depend-
ency for α(T) and β(T), yielding a remarkable difference
in predicted dose escalation with a much more pro-
nounced effect for the linear temperature dependency:
D95 ranges between 68.4Gy and 82.9Gy for the linear
interpolation compared to 52.5–56.9Gy for the piecewise
linear interpolation and 45.0-45.5Gy for radiotherapy
alone (Table 3). The piecewise linear interpolation re-
sults in a bending point in the DVH, separating the sec-
tions of the curve representing temperatures lower or
higher than 41 °C. Temperatures higher than 41 °C re-
sult in far more significant dose escalation than tempera-
tures below 41 °C.
Equivalent Dose distributions
Radiotherapy dose distributions for patient 1 with and
without hyperthermia are shown in Fig. 5. Temperature
sensitive LQ-parameters α(T) and β(T) were applied to
the GTV using the piecewise-linear interpolation to the
LQ-data listed in Table 2. The radiotherapy isodose
curves for the treatment of radiotherapy alone are there-
fore nearly identical to the equivalent radiotherapy iso-
dose curves accounting for the combination of
radiotherapy and hyperthermia, with exception for the
region inside the outlined GTV where a clear dose escal-
ation is evident. The image with the hyperthermia
temperature distribution overlaid clearly shows that the
gradual increase in temperature from the dorsal to the
Fig. 2 Image registration/matching. Radiotherapy and hyperthermia CT scans are rigidly matched by visual assessment of the bony anatomy,
followed by deformable registration using intensity-based deformable image registration software of Velocity Medical Solutions (Varian Medical
systems, Palo Alto). Left: overlay showing the excellent match of the RT-CT onto the HT-CT in the Region of Interest (ROI) indicated with the
dotted rectangle. Right: Outlines of rectum, cervix, bladder and part of the bony anatomy are shown in the RT-CT and the HT-CT
Table 2 LQ-parameters α and β used in the equivalent dose
calculations
Temperature [°C] α [Gy-1] β [Gy-2]
37 0.33 ± 0.06 0.02 ± 0.01
41 0.31 ± 0.05 0.09 ± 0.02
43 0.76 ± 0.04 0.09 ± 0.01
α and β values derived from clonogenic assays of SiHa cervical tumor cells
subjected to 1 h of hyperthermia treatment at 37, 41 or 43 °C [29]
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ventral side of the GTV is associated with a matching
gradual increase in effective radiation dose.
Discussion
Effect of Hyperthermia on Radiotherapy dose distribution
This study shows a substantial dose escalation of 7-
11Gy when radiotherapy is combined with hyperther-
mia (Table 3 and Fig. 4). Simulated temperatures
match fairly well with the measured temperatures.
Radiosensitization is not uniformly distributed, but
follows the temperature distribution of the hyperther-
mia treatment (Fig. 5). As a result, the effective radio-
therapy dose is no longer homogeneous within the
GTV. The absence of any effect on normal tissue out-
side the GTV is a result of our assumption that
hyperthermic radiosensitization is tumor selective
when radiotherapy and hyperthermia are given se-
quentially with a time interval of 1 h or longer. This
assumption is based on preclinical and clinical data.
Overgaard determined the effect of sequence and time
interval between radiotherapy and hyperthermia on
the thermal enhancement ratio (TER) in tumor and
normal skin in an in vivo tumor model. He found
that the TER in skin equaled that of tumor when
radiotherapy and hyperthermia are given simultan-
eously, but TER in skin quickly decreases to 1 when
the time interval is 1 h or longer as currently applied
in the clinic [41]. Clinical data for cervical cancer
confirm that hyperthermia does not enhance radiation
associated toxicity when the time interval between
hyperthermia and radiotherapy exceeds 1 h [13].
Temperature dependence of radiosensitization
The temperature dependence of the LQ-parameters
accounted for the temperature dependence of radiosen-
sitization. The large difference between the DVHs based
on the linear versus the piecewise-linear interpolation
for the temperature dependent α(T) and β(T) values can
be explained by overestimation of the effect of moderate
temperature elevations below 41 °C on the LQ-
parameters when using a linear interpolation. This over-
estimation of the effectiveness of hyperthermia results in
a very high computed effective dose escalation that is
not consistent with the known clinical results for hyper-
thermia from randomized trials. The dose escalation
computed for the piecewise-linear interpolation is more
realistic and closer to clinical reality. The piecewise lin-
ear interpolation results in a dose escalation that incre-
ments much stronger for temperatures above 41 °C,
which would imply that temperatures exceeding 41 °C
should be pursued in clinical hyperthermia. This demon-
strates the need to establish more exact data on the
temperature dependent LQ-parameters for the entire
clinically relevant hyperthermic temperature range (39–
43 °C).
The thermal dose effect relationship used in our simu-
lations is strong and was based on cell survival curves of
cervical cancer cell lines [29]. Clinical results for cervical
cancer confirm there is a correlation between thermal
dose and clinical results. Dinges et al. reported a correl-
ation between local tumor control and CEM43T90 (cu-
mulative equivalent minutes of T90 above 43 °C) for the
4 hyperthermia treatment sessions in a group of 18 pa-
tients with advanced carcinomas of the uterine cervix
Fig. 3 Temperature Volume Histogram. Temperature Volume Histogram (TVH) representing the simulated temperature distribution within the
GTV for patient 1, 2 and 3
Table 3 Radiotherapy and hyperthermia dose distribution
Pt# Simulated T90 [°C] T50 [°C] T10 [°C] D95 RT [Gy] RT + HT (lin) RT + HT (pw-lin) Measured T90 [°C] T50 [°C] T10 [°C]
1 39.2 40.1 41.2 45.2 68.4 52.5 39.5 40.0 40.5
2 39.7 40.5 41.0 45.5 76.2 55.5 39.3 40.1 40.8
3 40.4 41.1 41.8 45.0 82.9 56.9 40.5 41.4 42.2
Simulation of D95, T10, T50 and T90 in GTV and measurement of T10, T50 and T90 for patients 1 to 3
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Fig. 4 Dose Volume Histogram. Dose Volume Histogram reflecting the radiotherapy dose distribution within the GTV for patient 1, 2 and 3
comparing 3 different cases: Radiotherapy alone (RT only), radiotherapy and hyperthermia using a linear interpolation (RT + HT lin) or a piecewise
linear interpolation (RT + HT pw lin) to the α and β values from Franken et al. [29]. EBRT only, brachytherapy boost not taken into account
Fig. 5 Radiotherapy and hyperthermia dose distributions. Radiotherapy isodose curves (top left), equivalent radiotherapy isodose curves for
radiotherapy + hyperthermia (top right), idem with the hyperthermia temperature distribution overlaid as a color wash (bottom right) for patient
#1 with cervical cancer. Radiotherapy isodose curves overlaid on the CT scan of the patient made in hyperthermia position lying on a
hyperthermia water bolus. Gross tumour volume (GTV) is indicated by the bold red contour. The contribution of hyperthermia to equivalent
radiotherapy isodose is visible within the GTV and increases with increasing temperature in ventral direction. Vaginal pelotte for temperature
measurements during hyperthermia is visible adjacent to GTV
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treated with the combination of radiotherapy and hyper-
thermia (p = 0.019) [43]. Franckena et al. analysed treat-
ment outcome for 420 patients with locally advanced
cervical cancer treated with radiotherapy and hyperther-
mia and found a significant correlation between tumor
control and survival and CEM43T90 [44]. Franckena et
al. found an even more impressive correlation between
tumor control and survival and TRISE, a thermal dose
parameter based on the product of the median
temperature rise and the duration of heating [44].
Future perspectives
The temperature dependent LQ parameters used are
based on in vitro data and represent mainly the direct
radiosensitizing effect of hyperthermia on DNA repair
pathways [8]. A next step is inclusion of other rele-
vant factors and hyperthermia mechanisms like tissue
reoxygenation, direct tumor cell kill, tumor hypoxia
and repopulation. Most of these factors can be mod-
elled as changes in the LQ parameters. A recent re-
view discusses how these factors and mechanisms can
be incorporated [45].
We did not combine brachytherapy with hyperthermia
as combination with the individual 24 PDR pulses given
in a period of 24 h is technically impossible. The synergy
of hyperthermia given before or after the boost would be
limited to a small fraction of the boost. It was therefore
sufficient to determine the dose escalation of the EBRT
only to estimate the dose escalation of the full radiation
treatment due to hyperthermia. Inclusion of the
brachytherapy boost in the simulation is logical when
an HDR brachytherapy boost is given and combined
with hyperthermia, although this is not straightfor-
ward. Matching the tissue deformations of the brachy-
therapy planning MRI images with the external beam
radiotherapy CT planning scans is a very challenging
task and will require a precise form of deformable
image matching. Because of the steep gradients in the
brachy dose distribution small errors in geometry due
to the matching procedure would lead to relatively
large deviations in the brachy dose distribution recon-
structed in the EBRT scan. The most robust solution
minimizing the risk of introducing errors might be to
match the EBRT and hyperthermia datasets onto the
brachytherapy image set as the dose gradients in the
latter surpass dose gradients in the other sets.
An important step is to move from evaluation to
optimization of the combined treatment. The present
model evaluated the combined effect of hyperthermia
and radiotherapy, where both modalities were individu-
ally optimized without taking advantage of the synergis-
tic and complementary effects. In the second step the
combined treatment could be optimized. This may result
in higher hyperthermia doses being used close to organs
at risk with regard to radiotherapy.
The change in Tumor Control Probability (TCP) as a
result of adding hyperthermia would be an interesting
parameter to analyse. Computation of TCP was left out
of the present analysis as the brachytherapy given was
not included in the current workflow. For tumors
treated by EBRT only, conventional TCP models for
radiotherapy [46–48] can be used to calculate TCP based
on the equivalent radiation dose. Okunieff et al [47] esti-
mate that TCP increases with 1–3 %/Gy near TCD50
based on cervical cancer treatment data of Perez et al
[49, 50]. This corresponds to a 10–30 % increase in TCP
due to hyperthermia based on the median dose escal-
ation of 10Gy predicted for our 3 patients (Table 3). This
number is in line with the clinical data of cervical cancer
trials, e.g. the 26 % increase in tumor control by adding
hyperthermia to radiotherapy reported by van der Zee et
al. [13].
A very useful application of this model is to compare
the effectiveness of different treatment schedules and to
guide the design of clinical studies on dose escalation
using hyperthermia in a multi-modality setting.
Conclusions
This study demonstrated that radiosensitization by
hyperthermia can be converted to radiation-dose escal-
ation for cervical cancer patients using biological
modelling.
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